Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/20/24
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CAPRNewsWire • 01/03/24
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual MeetingPRNewsWire • 12/11/23
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial MarketsPRNewsWire • 10/31/23
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/26/23
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV CongressPRNewsWire • 10/13/23
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell TherapyPRNewsWire • 10/02/23
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung CancerPRNewsWire • 09/27/23
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisPRNewsWire • 09/13/23
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13thPRNewsWire • 09/06/23
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/23